Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

Table 2 Best overall response in the overall population

Response	Immune checkpoint inhibitor (n = 129)		Irinotecan-based chemotherapy (n = 234)
Response	No.	%	No.	%	P value
CR	4	3.1	1	0.4
PR	11	8.5	12	5.1
SD^a	30	23.3	92	39.3
PD	67	51.9	107	45.7
NE	17	13.2	22	9.4
Objective response rate^b	15	11.6	13	5.6	0.038
Disease control rate^c	45	34.9	105	44.9	0.064

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable
^aNon-CR/non-PD for cases without measurable disease were included in SD. ^bObjective response rate is defined as the proportion of patients with CR or PR as best overall response. ^cDisease control rate is CR + PR + SD (including nonCR/non-PD for cases with non-measurable disease only) as the best response

ISSN: 1471-2407